Dr. Michaelis on Safety Considerations With Venetoclax/Azacitidine in AML
Laura C. Michaelis, MD, discusses safety considerations with the combination of venetoclax and azacitidine in acute myeloid leukemia.
Dr. Michaelis on the Role of Interferon in MPNs
Laura C. Michaelis, MD, discusses the role of interferon in myeloproliferative neoplasms.
Dr. Michaelis on Potential Combination Strategies With Ruxolitinib in Myelofibrosis
Laura C. Michaelis, MD, discusses potential combination strategies with ruxolitinib in myelofibrosis.
Dr. Michaelis on Unanswered Questions in Myelofibrosis Treatment
Laura C. Michaelis, MD, discusses the direction of future myelofibrosis research.
Dr. Michaelis on Treating Patients With Myelofibrosis and Anemia
Laura C. Michaelis, MD, discusses the treatment of patients with myelofibrosis and anemia.
Dr. Michaelis on Fedratinib in Myelofibrosis Treatment
Laura C. Michaelis, MD, discusses the integration of fedratinib into the treatment sequence of myelofibrosis.
Further Understanding of Immune Mechanisms in Tumor Microenvironment Is Key to Advancing Immunotherapy in Solid Tumors
Navigating Systemic Therapy for RCC: Balancing Risk Status and Response
ADCs, Novel Targets Represent Next Wave of Treatment Advances in mCRPC
Precision Medicine in Prostate Cancer Care: Keeping Up With Evolving Guidance for Testing and Decision Making
2 Clarke Drive Cranbury, NJ 08512